Germany's IQWiG Calls For Wider Availability Of Comparative Effectiveness Data
This article was originally published in The Pink Sheet Daily
Executive Summary
A draft law also would raise the profile of Germany's cost-effectiveness watchdog, but perhaps not empower it as much as it hopes.
You may also be interested in...
European Regulatory Round-Up: New Faces; Revised Guidances; More Cost Controls
A new chairman will take the helm of Germany's G-BA panel at a pivotal time for AMNOG implementation; the European Medicines Agency issues guidances in oncology drug development and genotoxicity; more regulatory updates.
German Rebate Contracts Under Threat From Legislation Promoting Patient Choice
Proposals designed to expand patient choice over which medicines they take risk undermining Germany's discount contract system, thereby increasing drug costs, the country's largest health insurer, AOK, says.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.